Detection of acute cases of human immunodeficiency virus (HIV) infection by the direct detection of HIV antigen or HIV nucleic acid assays is well known with an estimated 5-9 days reduction in the pre-seroconversion 'window period' by the detection of HIV specific antibodies. The aim of this study w
HCV core antigen and combination (antigen/antibody) assays for the detection of early seroconversion
β Scribed by George J. Dawson
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 84 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Detection of antibodies against hepatitis C virus (HCV) and/or detection of HCV RNA by nucleic acid testing (NAT) are the commonly utilized methods for detecting exposure to HCV in both blood screening and diagnostic laboratories. While several HCV core antigen tests have been developed over the last 10 years, these assays have not gained wide acceptance in routine laboratory practices, due in part to inadequate sensitivity. Over the last several years, improvements have been made in the formulation of the HCV core antigen assays that have resulted in significant sensitivity improvements. Recent studies indicate that between 85% and 98% of preseroconversion samples that are HCV RNA positive are detected with the improved HCV core antigen assays. These improved assays include stand-alone HCV core antigen tests and HCV antigen/antibody combination tests. As such, these assays could provide an alternative to HCV NAT in blood banks where such testing has not already been implemented, and may be utilized in diagnostic laboratories to identify early HCV infection. J. Med. Virol.
π SIMILAR VOLUMES
## Abstract A new, sensitive enzyme immunoassay has been developed for detecting and quantifying total hepatitis C virus (HCV) core antigen in antiβHCV positive or negative sera (β__trak__β__C__β’β, Ortho Clinical Diagnostics, Raritan, NJ). The purpose of this study was to evaluate the performance o
Monoclonal antibodies (MAbs) were generated by immunizing mice with a truncated recombinant protein corresponding to the immunodominant region (residues 1-120) of hepatitis C virus (HCV) nucleocapsid protein. The specific recognition by either human sera or mouse monoclonal antibodies of overlapping
## Abstract The ability of the total hepatitis C virus (HCV) core antigen assay was evaluated for monitoring the therapeutic responses of HCVβinfected patients treated with interferon. The ability to detect and quantitate an independent structural protein component of HCV, in the presence of circul
## Abstract Drug users and particularly, injecting drug users, are at increased risk for infection with hepatitis C virus (HCV). The aims of the study were to simultaneously detect HCV core antigen and specific antibodies in sera from Saudi drug users using the new HCV combination assay and to comp
IgM antibody against core antigen of the hepatitis B virus (anti-HBc IgM) was selectively determined by a new enzyme immunoassay (EIA). Microtiter plates were coated with anti-human micro chain immunoglobulin. On addition of serum IgM is bound by a factor of about 4,000 more than IgG. After removing